Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36316612/
doi: 10.1007/s40256-022-00552-7. Online ahead of print. 1 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Mail Stop C238, 12850 E. Montview Blvd, Aurora, CO, 80045, USA. [email protected]. 2 Department of Integrated Medical Science, Cardiology and Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA.
Conclusions: Further LDL-C reductions through the addition of BA EZE FDC to maximally tolerated statins are predicted to reduce major adverse cardiovascular events compared with the addition of EZE. Benefits are potentially greater among those with higher starting LDL-C.
• Source: American Journal of Cardiovascular Drugs
• Conclusion: “Further LDL-C reductions through the addition of BA+EZE FDC [fixed-dose combination of bempedoic acid plus ezetimibe] to maximally tolerated statins are predicted to reduce major adverse cardiovascular events compared with the addition of EZE. Benefits are potentially greater among those with higher starting LDL-C.”
• U.S. researchers focused on the potential benefits and place in therapy for BA+EZE FDA compared with EZE in patients who are unable to achieve their LDL-C goal on maximally tolerated statins. In the study, there were 86 patients in each group.
• “Among patients requiring up to a 40% reduction in LDL-C, BA+EZE FDC is predicted to provide a greater risk reduction than EZE alone across all patients and avoids the largest incremental number of CV events relative to EZE among those with a starting LDL-C between 110 and 140 mg/dL,” the authors wrote. “ Our findings support the conclusions of an independent advisory panel recommending the use of BA+EZE FDC for patients unlikely to reach LDL-C goals with the addition of EZE alone.”
• Limitations of the current study include issues with the model used and a smaller sample size.